Mufg Securities Emea PLC Incyte Corp Transaction History

Mufg Securities Emea PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$63.34 - $74.11 $2.85 Million - $3.33 Million	-45,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $3.09 Million - $3.78 Million	45,000 New	45,000 $3.1 Million
Q2 2020 Aug 13, 2020	SELL	$74.18 - $108.93 $22.7 Million - $33.4 Million	-306,300 Closed	0 $0
Q1 2020 May 12, 2020	BUY	$63.18 - $85.97 $18.5 Million - $25.2 Million	292,800 Added 2168.89%	306,300 $22.4 Million
Q4 2019 Feb 11, 2020	BUY	$73.04 - $95.72 $986,040 - $1.29 Million	13,500 New	13,500 $1.18 Million
Q4 2018 Feb 14, 2019	SELL	$58.5 - $69.94 $279,805 - $334,523	-4,783 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$61.75 - $74.23 $283,185 - $340,418	4,586 Added 2327.92%	4,783 $330,000
Q2 2018 Aug 01, 2018	BUY	$60.85 - $83.98 $11,987 - $16,544	197 New	197 $13,000

653

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.1B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Mufg Securities Emea PLC, based on Form 13F filings with the SEC.

Stay updated on Mufg Securities Emea PLC with notifications on news.